Faruqi & Faruqi, LLP reminds investors of the August 10, 2026 deadline to seek lead plaintiff in a securities class action against Erasca, Inc. The lawsuit alleges the company and its executives made false or misleading statements about preclinical data for drug candidate ERAS-0015, which was based on improper comparisons to Revolution Medicines, Inc. and placed Erasca at risk of patent and trade secret violations. On April 27, 2026, Erasca disclosed a letter from RevMed alleging patent infringement and improper data comparisons, causing shares to fall 10.9% from $21.49 to $19.15. Later that day, Erasca reported preliminary Phase 1 data revealing a patient death and acknowledged prior comparisons were not based on head-to-head trials, leading to an additional 45% drop to $9.90 per share. Investors who purchased Erasca securities between January 14, 2025 and April 26, 2026 and suffered losses may contact the firm to discuss their legal rights.
Erasca IncSecurities class action lawsuit alleging false statements about preclinical data and patent/trade secret violations, causing significant stock drop.
Revolution Medicines IncMentioned as the company whose data was improperly compared, and as alleging patent infringement against Erasca.